Literature DB >> 12734273

Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

M A Pfaller1, S A Messer, L Boyken, S Tendolkar, R J Hollis, D J Diekema.   

Abstract

We examined the susceptibilities to fluconazole of 559 bloodstream infection isolates of Candida glabrata and grouped the isolates by patient age and geographic location within the United States. Susceptibility of C. glabrata to fluconazole was lowest in the Pacific (44%) and East South Central (47%) regions and was highest in the West South Central region (82%) (regions are as designated by the U.S. Bureau of the Census). Isolates from pediatric patients were virtually all susceptible to fluconazole, whereas the highest frequency of resistance was observed in isolates from patients 16 to 64 years of age.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734273      PMCID: PMC154732          DOI: 10.1128/JCM.41.5.2176-2179.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

Review 1.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

2.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

3.  Nosocomial Candida glabrata colonization: an epidemiologic study.

Authors:  J A Vazquez; L M Dembry; V Sanchez; M A Vazquez; J D Sobel; C Dmuchowski; M J Zervos
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

6.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Authors:  D J Diekema; S A Messer; A B Brueggemann; S L Coffman; G V Doern; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

8.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland.

Authors:  Lena Rós Asmundsdóttir; Helga Erlendsdóttir; Magnús Gottfredsson
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.

Authors:  J R Wingard; W G Merz; M G Rinaldi; C B Miller; J E Karp; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more
  27 in total

1.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.

Authors:  M Drago; M M Scaltrito; G Morace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

5.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

7.  Skn7p is involved in oxidative stress response and virulence of Candida glabrata.

Authors:  Tomomi Saijo; Taiga Miyazaki; Koichi Izumikawa; Tomo Mihara; Takahiro Takazono; Kosuke Kosai; Yoshifumi Imamura; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Katsunori Yanagihara; Shigeru Kohno
Journal:  Mycopathologia       Date:  2009-08-20       Impact factor: 2.574

8.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Inner kinetochore of the pathogenic yeast Candida glabrata.

Authors:  Tanja Stoyan; John Carbon
Journal:  Eukaryot Cell       Date:  2004-10

10.  Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.

Authors:  Sélène Ferrari; Françoise Ischer; David Calabrese; Brunella Posteraro; Maurizio Sanguinetti; Giovanni Fadda; Bettina Rohde; Christopher Bauser; Oliver Bader; Dominique Sanglard
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.